Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Merck
McKesson
Boehringer Ingelheim
Moodys

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DASIGLUCAGON HYDROCHLORIDE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for dasiglucagon hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02916251 ↗ ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon Completed Zealand Pharma Phase 2 2016-12-01 The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*) administered subcutaneously to patients with type 1 diabetes mellitus under euglycaemic and hypoglycaemic conditions and compared to marketed glucagon. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
NCT02971228 ↗ Feasibility Trial Testing the Bionic Pancreas With ZP4207 Completed Beta Bionics, Inc. Phase 2 2016-11-01 The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
NCT02971228 ↗ Feasibility Trial Testing the Bionic Pancreas With ZP4207 Completed Massachusetts General Hospital Phase 2 2016-11-01 The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
NCT02971228 ↗ Feasibility Trial Testing the Bionic Pancreas With ZP4207 Completed Zealand Pharma Phase 2 2016-11-01 The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
NCT03216226 ↗ A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus Completed SynteractHCR Phase 3 2017-06-28 The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for dasiglucagon hydrochloride

Condition Name

Condition Name for dasiglucagon hydrochloride
Intervention Trials
Hypoglycemia 9
Diabetes Mellitus, Type 1 4
Type 1 Diabetes 3
Congenital Hyperinsulinism 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for dasiglucagon hydrochloride
Intervention Trials
Hypoglycemia 11
Diabetes Mellitus, Type 1 9
Diabetes Mellitus 9
Congenital Hyperinsulinism 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for dasiglucagon hydrochloride

Trials by Country

Trials by Country for dasiglucagon hydrochloride
Location Trials
United States 20
Germany 7
Denmark 4
Israel 3
United Kingdom 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for dasiglucagon hydrochloride
Location Trials
California 4
Texas 3
Pennsylvania 3
Colorado 3
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for dasiglucagon hydrochloride

Clinical Trial Phase

Clinical Trial Phase for dasiglucagon hydrochloride
Clinical Trial Phase Trials
Phase 3 6
Phase 2/Phase 3 2
Phase 2 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for dasiglucagon hydrochloride
Clinical Trial Phase Trials
Completed 11
Recruiting 3
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for dasiglucagon hydrochloride

Sponsor Name

Sponsor Name for dasiglucagon hydrochloride
Sponsor Trials
Zealand Pharma 13
Steno Diabetes Center Copenhagen 2
Beta Bionics, Inc. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for dasiglucagon hydrochloride
Sponsor Trials
Industry 16
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Dow
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.